Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM9RTXM)

Drug Name
LY3164530 Drug Info
Indication
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
TTD Drug ID
DM9RTXM

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Modulator [3]
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Proto-oncogene c-Met (MET) DTT MET 6.737 6.293 7.744 6.879
Epidermal growth factor receptor (EGFR) DTT EGFR 6.045 4.991 5.317 5.252
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Advanced cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proto-oncogene c-Met (MET) DTT MET 1.08E-03 -0.24 -0.4
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02221882) A Study of LY3164530 in Participants With Cancer
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.